Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma
Purpose: Histone deacetylase inhibitors can alter gene expression and mediate diverse
antitumor activities. Herein, we report the safety and activity of the histone deacetylase …
antitumor activities. Herein, we report the safety and activity of the histone deacetylase …
Tumor lysis syndrome: a systematic review of case series and case reports
BM Firwana, R Hasan, N Hasan, F Alahdab… - Postgraduate …, 2012 - Taylor & Francis
Tumor lysis syndrome (TLS) is a clinical condition that is caused by a massive lysis of tumor
cells that accumulate very rapidly and disturb hemodynamics. This oncologic emergency …
cells that accumulate very rapidly and disturb hemodynamics. This oncologic emergency …
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic …
Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of
intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell …
intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell …
A review of tumour lysis syndrome with targeted therapies and the role of rasburicase
P Bose, O Qubaiah - Journal of clinical pharmacy and …, 2011 - Wiley Online Library
What is known and Objective: Tumour lysis syndrome (TLS) is an oncologic emergency with
potentially devastating consequences classically associated with cytotoxic chemotherapy. In …
potentially devastating consequences classically associated with cytotoxic chemotherapy. In …
Panobinostat in lymphoid and myeloid malignancies
Introduction: Histone deacetylase inhibitors (HDACIs) are a class of antineoplastic agent
targeting the epigenome, specifically chromatin remodelling, resulting in modulation of …
targeting the epigenome, specifically chromatin remodelling, resulting in modulation of …
European Journal of Medicinal Chemistry Rationally Designed Febuxostat-Based Hydroxamic Acid and its pH-Responsive Nanoformulation Elicits Anti-Tumor Activity
ZY Liao, PY Chen, NV Rao, J Mathew… - European Journal of …, 2024 - Elsevier
Attempts to furnish antitumor structural templates that can prevent the occurrence of drug-
induced hyperuricemia spurred us to generate xanthine oxidase inhibitor-based hydroxamic …
induced hyperuricemia spurred us to generate xanthine oxidase inhibitor-based hydroxamic …
Diagnostic exercise: sudden death in a mouse with experimentally induced acute myeloid leukemia
E Radaelli, F Marchesi, V Patton… - Veterinary …, 2009 - journals.sagepub.com
A 22-week-old female 129/SvEv mouse suddenly died in the context of an experiment aimed
at defining the efficacy of valproic acid in a mouse model of PML/RARα-induced acute …
at defining the efficacy of valproic acid in a mouse model of PML/RARα-induced acute …
[图书][B] Understanding the Relevance of Epigenetic Reprogramming for Resistance to Hdac Inhibitors in Cancer Cells
V Perikala - 2016 - search.proquest.com
Therapeutic responses to Histone deacetylase (HDAC) inhibitors (HDACi) in many cancers
are well described but development of resistance to HDACi is a major stumbling block …
are well described but development of resistance to HDACi is a major stumbling block …